For example, in colorectal cancers overexpressing EGFR, the presence of a strongly activating KRAS mutation eliminates the effectiveness of EGFR-targeting antibodies, even in tumors with highly overexpressed EGFR (48, 49). The gene discussed is KRAS; the disease is colorectal cancer.